Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here's Why [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
now . Mizuho lifted the price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $106 from $91 on March 18, reiterating an Outperform rating on the shares and telling investors in a research note that the primary catalyst for the company this year is Pfizer's tafamidis litigation bench trial from April 27 to May 5, which holds the potential to materially impact the stock. The firm added that it raised the price target based on factors such as the continued strength of Attruby, updated infigratinib data in achondroplasia and hypochondroplasia, and the potential upside from a favorable litigation outcome, which can add considerable value per $1 billion in peak sales. BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights In another development, BridgeBio Pharma, Inc. (NASDAQ:BBIO) was initiated with an Outperform rating on March 10 by William Blair, with a fair value estimate of $93.03 per share. The firm told investors in a research note that the company is a commercial-stage
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54GlobeNewswire
- BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 [Yahoo! Finance]Yahoo! Finance
- BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9GlobeNewswire
- Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative? [Yahoo! Finance]Yahoo! Finance
- BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific SessionsGlobeNewswire
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 4/2/26 - Form SCHEDULE
- 3/30/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- BBIO's page on the SEC website